Current Good Manufacturing Practice (GMP) in the pharmaceutical and medical device industry is a Food and Drug Agency (FDA) mandated requirement to ensure all production activities are executed by trained operatives following pre-approved documented procedures that utilize only fully validated and calibrated equipment, facilities and utilities. (21 CFR Part 820/210/211/11 Refers.)
FDA regulations use the phrase "current good manufacturing practices cgmp's" (GLP/GMP Validation) to describe these guidelines. Courts may theoretically hold that a drug product is adulterated even if there is no specific regulatory requirement that was violated as long as the process was not performed according to industry standards. By June 2010, the same GLP/GMP Validation requirements will apply to all manufacturers of dietary supplements. The World Health Organization (WHO) version of cGMP Validation is used by pharmaceutical regulators and the pharmaceutical industry in over one hundred countries worldwide, primarily in the developing world. The European Union's cGMP (EU-GMP) enforces similar requirements to WHO cGMP Validation, as does the Food and Drug Administration's version in the US. Similar cGMP Validations are used in other countries, with Australia, Canada, Japan, Singapore and others having highly developed/sophisticated cGMP requirements. In the United Kingdom, the Medicines Act (1968) covers most aspects of cGMP in what is commonly referred to as "The Orange Guide", which is named so because of the colour of its cover; it is officially known as Rules and Guidance for Pharmaceutical Manufacturers and Distributors.
Current Manufacturing Practices (for medicinal products) is that part of Quality Assurance which ensures that Medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization or product specification. cGMP is concerned with both production and quality control.
Current Good Manufacturing Practice cGMP, are issued by regulatory authorities throughout the world, country by country and region by region. In general they list minimum standards for the safe manufacture, storage and distribution of medicinal drugs, devices and all associated records. GMP rules and FDA regulations are just as enforceable (in the country of their origin) as is common criminal law. Because pharmaceutical products and their raw materials are manufactured and distributed internationally, collaborations between manufacturing companies has led to national authorities introducing commonality in many specifications and standards; this is a continuous and ongoing process.
There are several different sections to GLP/GMP Validation requirements as detailed in CFR’s so it is essential to study those applicable to your processes. I.E. Medical Device, Biotech, Human Food, or Drugs. Manufacturers must adapt a very positive and proactive approach in conforming and enforcing the rules and guidelines throughout their entire manufacturing, inspecting, storing and distribution processes. They are required to implement processes and procedures that comply with the requirements listed in the applicable continued Good Manufacturing Practices (cGMP) and gain approval from their regulatory authority that they comply with all of these regulations prior to being allowed to release their produce for public or prescribed use. They are subject to continuous monitoring of this regulated state.
Good Manufacturing Practices cGMP and FDA regulations have been developed to ensure that medicinal pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use. They have been developed and introduced in 1962 in response to the US public’s concern about the safety, efficacy and overall quality of drugs. In the United States the regulations are called cGMP to take into account that the regulations are not static but rather dynamic. They are defined in Title 21 of the U.S. Code of Federal Regulations: 21 CFR 210 – current Manufacturing Practice for drugs in general and 21 CFR 211 – Current Manufacturing Practice, for finished pharmaceuticals. In 1996 the FDA proposed a significant revision of the regulation. Any drug marketed in the US must first receive FDA approval, and must be manufactured in accordance with the US cGMP regulations. Because of this, FDA regulations have set an international regulation benchmark for pharmaceutical manufacturing.
In Europe local Good Manufacturing Practices cGMP, regulations exist in many countries. They are based on the European Union (EU) directive: Manufacturing Practice for Medicinal Products in the European Community. This EU GMP is necessary to permit free trade in medicinal products between the member countries. Regulations in the EU allow for the marketing of a new drug in the twelve member countries with a single marketing approval.
The EU GMP is intended to establish a minimum manufacturing standard for all member states. The EU directive has been widely harmonized with the Guide to current excellent Manufacturing Practice for Pharmaceutical Products as developed by the Pharmaceutical Inspection Convention (PIC).10
Search Our Store
To find a specific document enter full details in Search Box Below. The more defined the search is the more precise the search findings will be.
Select Preferred Language
When assistance is required; please contact us on TOLL-FREE 877-462-4048
If out of office hours; please leave a voice message.
This Validation, Risk & Requirements Plan (VrrP) is one document designed specifically to replace three. The contents of the three original documents were completely revised and edited into a more compact and interactive format. Resulting in the document becoming notably easier to use and quicker to review and amend. This new format will make a very significant difference to the man hours required to produce and execute these documents. There will also be a very noticeable reduction in the time required for the reviewing and approving tasks. This new document titled the VrrP replaces the VP, VRA & URS and now compliments our equally new 4Q Protocol, which integrates the DQ/IQ/OQ/PQ into one document. This is an essential step forward for companies seeking to reduce validation costs without sacrificing regulatory compliance.
This new 4Q Equipment Validation Protocol (4Q-Equip) has been designed specifically to replace four standard protocols. By taking the contents of the these four protocols and carefully weaving them into one notably easy to use protocol, we have made significant progress in reducing validation paperwork. Reductions of up to 75% have been quoted as the likely total. Integrating the old style DQ/IQ/OQ/PQ protocols into one 4Q document will be an enormous savings in man hours in the authoring, reviewing, updating and approving tasks. With the simultaneous introduction of the new Validation risk & Requirements Plan (VrrP) which integrates the VP, VRA & URS into one document - equipment validation has been reduced to two document.
This quite revolutionary two document package is all that is required to fully validate; to cGMP standards, equipment used in a regulated facility. A lot of effort has gone into ensuring that repetitive instructions and actions have been designed out and innovative and intuitive risk-based methodologies have been incorporated. Both documents are prefaced with a methods Standard Operating Practice (SOP) document. These SOP’s lead you through the task of converting these highly detailed templates into your very own company bespoke protocols. The hyperlinks and cross-references within the package are; not only unique, but also highly cost effective and intuitive to use. Each document is preloaded with the test scripts (complete with acceptance criteria). All test and inspection scripts are written in MS word, to facilitate simple editing of text, layout, tables and schematics.
During a regulatory visit the inspectors do expect to see a complete suite of validation documents in place for each validation task. The use and scope of the individual documents has been documented, discussed and explained in detail. It is therefore obviously best policy to have in place exactly what the regulator is looking for. The use of a document packages ensures a multitude of regulatory requirements are catered for and possibly a similar multitude of pitfalls, blunders and omissions are anticipated and negated